OBJECTIVE: Multiple diagnostic modalities may be needed to establish the source of excessive androgen production in women. The role of selective venous catheterization in this process has not been established fully. DESIGN: A study of hyperandrogenaemic subjects and literature review. PATIENTS: Four hyperandrogenaemic women and an additional 132 previously reported cases with available testing data and a pathological diagnosis were evaluated. MEASUREMENTS: Serum androgens, diagnostic imaging and ovarian venous effluent sampling. Criteria to distinguish ovarian tumours from other ovarian conditions and to localize the lesion(s) were evaluated. RESULTS: Basal peripheral testosterone levels >or= 4.51 nmol/l (>or= 130 ng/dl) discriminated ovarian tumours from benign causes of hyperandrogenism (sensitivity: 93.8%, 95% CI 85.0-98.2; specificity: 77.8%, 95% CI 66.4-86.7). Single lesions produced higher ipsilateral testosterone concentrations (612.6 +/- 162.0 nmol/l; 17 653 +/- 4670 ng/dl) compared to contralateral values (26.4 +/- 5.2 nmol/l; 761 +/- 150 ng/dl). In women with peripheral testosterone >or= 4.51 nmol/l, a right-to-left (R:L) ovarian testosterone ratio >or= 1.44 correctly identified all 18 women with right-sided tumours and misclassified two with bilateral lesions; 12 out of 14 women with left-sided or bilateral lesions had a lower R:L value. When this criterion was combined with a left-to-right (L:R) ovarian testosterone effluent ratio of > 15 to identify left-sided tumours, overall 66% of women were correctly categorized. CONCLUSIONS: Peripheral testosterone concentrations identified ovarian androgen-producing tumours, and venous sampling could correctly localize 66% of these, suggesting a role for sampling when imaging studies are not revealing.
OBJECTIVE: Multiple diagnostic modalities may be needed to establish the source of excessive androgen production in women. The role of selective venous catheterization in this process has not been established fully. DESIGN: A study of hyperandrogenaemic subjects and literature review. PATIENTS: Four hyperandrogenaemic women and an additional 132 previously reported cases with available testing data and a pathological diagnosis were evaluated. MEASUREMENTS: Serum androgens, diagnostic imaging and ovarian venous effluent sampling. Criteria to distinguish ovarian tumours from other ovarian conditions and to localize the lesion(s) were evaluated. RESULTS: Basal peripheral testosterone levels >or= 4.51 nmol/l (>or= 130 ng/dl) discriminated ovarian tumours from benign causes of hyperandrogenism (sensitivity: 93.8%, 95% CI 85.0-98.2; specificity: 77.8%, 95% CI 66.4-86.7). Single lesions produced higher ipsilateral testosterone concentrations (612.6 +/- 162.0 nmol/l; 17 653 +/- 4670 ng/dl) compared to contralateral values (26.4 +/- 5.2 nmol/l; 761 +/- 150 ng/dl). In women with peripheral testosterone >or= 4.51 nmol/l, a right-to-left (R:L) ovarian testosterone ratio >or= 1.44 correctly identified all 18 women with right-sided tumours and misclassified two with bilateral lesions; 12 out of 14 women with left-sided or bilateral lesions had a lower R:L value. When this criterion was combined with a left-to-right (L:R) ovarian testosterone effluent ratio of > 15 to identify left-sided tumours, overall 66% of women were correctly categorized. CONCLUSIONS: Peripheral testosterone concentrations identified ovarian androgen-producing tumours, and venous sampling could correctly localize 66% of these, suggesting a role for sampling when imaging studies are not revealing.
Authors: R Azziz; L A Sanchez; E S Knochenhauer; C Moran; J Lazenby; K C Stephens; K Taylor; L R Boots Journal: J Clin Endocrinol Metab Date: 2004-02 Impact factor: 5.958
Authors: G A Kaltsas; J J Mukherjee; B Kola; A M Isidori; J A Hanson; J E Dacie; R Reznek; J P Monson; A B Grossman Journal: Clin Endocrinol (Oxf) Date: 2003-07 Impact factor: 3.478
Authors: André M Faria; Ricardo V Perez; José A M Marcondes; Daniel S Freire; Roberto Blasbalg; José Soares; Kleber Simões; Sylvia A Y Hayashida; Maria A A Pereira Journal: Nat Rev Endocrinol Date: 2011-02-15 Impact factor: 43.330
Authors: Rosa Maria Paragliola; Francesco Torino; Paola Senes; Laura Castellino; Vanda Salutari; Alfredo Pontecorvi; Giovanni Scambia; Salvatore M Corsello Journal: Endocrine Date: 2013-10-04 Impact factor: 3.633
Authors: Jaya M Mehta; Jeffrey L Miller; Anthony J Cannon; Stacey K Mardekian; Lawrence C Kenyon; Serge A Jabbour Journal: Case Rep Endocrinol Date: 2014-06-19